Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717702 · ClinicalTrials.gov registry record
Stress-Delta Biomarkers for Acute Coronary Syndrome Risk Stratification
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 125
- Enrollment target
NCT02717702: Completed study, sponsored by Duke University.
NCT02717702 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 125 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02717702 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
Study Summary
Acute Coronary Syndrome (ACS) is a serious heart condition that is a leading cause of death in America. Cardiac stress testing is currently the best test to non-invasively identify which patients might be having ACS and may need more invasive testing such as a cardiac catheterization (placing a tube in the heart) for coronary angiogram (invasive mapping of the blood vessels of the heart). However, stress tests require imaging by highly trained specialists and even then may not correctly categorize a small minority of patients being evaluated for ACS. Advances in blood tests may now allow detection of the very early stages of heart blood vessel blockage via a simple blood test. The investigators seek to determine whether these blood tests can help to better identify patients with ACS. The study will also store any extra blood sample that may be left over for future use.
Primary Outcome
1-hour Post-Stress Troponin I - Resting Baseline Troponin I)/ Resting Baseline Troponin I
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-08-10 |
| Est. Completion | 2019-06-11 |
What the finished NCT02717702 record still lists
NCT02717702 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02717702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02717702 about?
NCT02717702 is a clinical study titled "Stress-Delta Biomarkers for Acute Coronary Syndrome Risk Stratification". Acute Coronary Syndrome (ACS) is a serious heart condition that is a leading cause of death in America. Cardiac stress testing is currently the best test to non-invasively identify which patients might be having ACS and may need more invasive testing such as a cardiac catheterization (placing a tube...
What is the current status of trial NCT02717702?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2016-08-10. Estimated completion is 2019-06-11.
Who is sponsoring clinical trial NCT02717702?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI